flure-BYE-proe-fen 
Contraindicated in:
Use Cautiously in:
CV: HF, MI, STROKE, edema, hypertension, palpitations.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, ↑ sweating, rash.
EENT: blurred vision, corneal opacities, tinnitus.
F and E: hyperkalemia.
GI: GI BLEEDING, abdominal pain, heartburn, nausea, bloated feeling, constipation, diarrhea, drug-induced hepatitis, stomatitis.
GU: incontinence.
Hemat: blood dyscrasias, prolonged bleeding time.
MS: myalgia.
Neuro: depression, dizziness, drowsiness, headache, insomnia, psychic disturbances.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), chills, fever.
Drug-Drug:
Drug-Natural Products:
Therapeutic Classification: antirheumatics, nonopioid analgesics
Pharmacologic Classification: nonsteroidal anti-inflammatory drugs (NSAIDs)
Absorption: Well absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 99%.
Metabolism/Excretion: Mostly metabolized by the liver (primarily by CYP2C9). Patients who are poor CYP2C9 metabolizers may have reduced metabolism of flurbiprofen which may lead to ↑ toxicity). 20–25% excreted unchanged by the kidneys.
Half-life: 3–6 hr.
NDC Code*